Medicare to Launch Pilot Program Covering GLP-1 Weight-Loss Drugs

2026-06-30

The BareStory

Medicare is launching a temporary demonstration program on July 1, 2026, to cover GLP-1 weight-loss medications. Under the "Medicare GLP-1 Bridge" program, eligible patients will pay a $50 monthly copay for specific obesity drugs, including Wegovy, Zepbound, and Foundayo. This marks the first time Medicare will assist in paying for drugs prescribed solely for obesity, utilizing a specific legal provision to bypass a federal ban on Medicare Part D coverage for weight-loss treatments.

The program will run as an 18-month trial ending December 31, 2027. To qualify, patients must have Part D coverage and meet specific clinical criteria, including a body mass index (BMI) of at least 35, or a lower BMI with related conditions like hypertension, prediabetes, or heart disease. The $50 copay will not count toward patients' Part D deductibles or their $2,100 annual out-of-pocket limits, and coupons cannot be used to reduce the cost further.

The health care research nonprofit KFF estimated that about 3.8 million beneficiaries will qualify, while a Centers for Medicare & Medicaid Services (CMS) official expected several million to participate. Prior authorization requests must be submitted to Humana, which CMS contracted to process approvals. While some medical experts called the eligibility criteria appropriate, other physicians warned that the authorization process could strain clinics and pharmacies.

An analyst with Leerink Partners projected the program could generate more than $1 billion in annual revenue for drugmakers Eli Lilly and Novo Nordisk. However, health experts expressed concern about the program's scheduled expiration in late 2027. Because these are long-term treatments, patients may lose access unless Congress passes permanent legislation, CMS issues an extension, or manufacturers lower their pricing to match the copay.

Left Perspective

Dismantling Healthcare Disparities
Resisting Corporate Exploitation
Confronting the Access Cliff

Right Perspective

Preserving Fiscal Discipline
Minimizing Administrative Friction
Avoiding Market Distortions

Left Perspective

• Dismantling Healthcare Disparities Obesity is a complex medical condition, and prioritizing health equity requires removing the financial barriers that prevent low-income seniors from accessing essential care. By utilizing a legal provision to bypass the federal ban on Medicare Part D coverage for weight-loss treatments, this program establishes a vital lifeline for up to 3.8 million vulnerable beneficiaries. Offering Wegovy, Zepbound, and Foundayo for a $50 monthly copay ensures that critical health interventions are no longer reserved exclusively for the wealthy. This pilot represents a progressive leap toward treating obesity with the clinical seriousness it deserves.

• Resisting Corporate Exploitation While expanding access is crucial, public programs must not serve as unchecked revenue engines for private pharmaceutical giants. Projecting over $1 billion in annual revenue for Eli Lilly and Novo Nordisk demonstrates how federal subsidies can enrich corporations without demanding concessions on pricing. Furthermore, preventing the $50 copay from counting toward patients' Part D deductibles or their $2,100 annual out-of-pocket limits exposes a system designed to shield drugmakers from market pressures while shifting financial risk onto patients. True consumer advocacy requires pairing access with robust price controls to prevent corporate extraction of public funds.

• Confronting the Access Cliff A temporary, 18-month pilot program introduces unacceptable instability for patients managing a chronic, long-term condition. Ending the program on December 31, 2027, creates a dangerous health hazard where millions of seniors could suddenly lose access to life-altering medications. This artificial cliff exposes the cruelty of temporary policy fixes, highlighting the urgent need for permanent legislative action rather than administrative stopgaps. Without structural reform to permanently strike down the Medicare Part D ban, patients remain pawns to shifting regulatory whims.

Right Perspective

• Preserving Fiscal Discipline Entitlement programs must be managed with strict fiscal stewardship to ensure long-term systemic stability. Bypassing the statutory federal ban on Medicare Part D coverage for weight-loss drugs via administrative maneuvers sets a concerning precedent that undermines the rule of law. Subsidizing expensive therapies for a massive potential patient pool—with KFF estimating 3.8 million qualifiers—threatens to overwhelm the federal budget with unpredictable liabilities. Protecting the financial integrity of Medicare requires adhering to established legislative boundaries rather than expanding costly benefits through temporary, backdoor mechanisms.

• Minimizing Administrative Friction Injecting millions of new patients into a complex approval pipeline threatens to clog an already overburdened clinical system. Tasking Humana with processing prior authorizations for a vast new class of drugs will create administrative bottlenecks that strain local clinics and pharmacies. Physicians and pharmacists will be forced to divert valuable time away from direct patient care to manage bureaucratic red tape and verify complex eligibility criteria, such as specific BMI thresholds and co-occurring conditions. A stable healthcare system must prioritize administrative simplicity over labor-intensive regulatory hurdles.

• Avoiding Market Distortions Artificially subsidizing demand for high-cost drugs through an arbitrary, short-term pilot distorts natural market dynamics. Injecting public funds to guarantee a $50 copay shields consumers from actual costs, disincentivizing the organic price competition that eventually lowers drug prices. This intervention guarantees windfalls for specific manufacturers like Eli Lilly and Novo Nordisk while setting up an unsustainable policy cliff in late 2027. Once the subsidy expires, the government will face immense pressure to permanently fund an expensive benefit, demonstrating how short-term interventions inevitably lead to permanent market distortions and long-term taxpayer liabilities.

How it may affect me

As a U.S. reader:

• Eligible Medicare Part D beneficiaries with a body mass index of 35 or higher, or a lower BMI with related health conditions, can temporarily access specific GLP-1 weight-loss drugs for a fifty-dollar monthly copay starting July 1, 2026.

• Participating patients will have to pay the fifty-dollar copay without it counting toward their Part D deductibles or their twenty-one hundred dollar annual out-of-pocket limits.

• Patients face a long-term risk of losing access to these ongoing treatments when the pilot program expires on December 31, 2027, unless permanent laws are passed, the program is extended, or drugmakers lower prices.

• The general public may experience administrative delays and reduced direct care time at local clinics and pharmacies as healthcare staff manage a high volume of prior authorization requests.

Medicare to Launch Pilot Program Covering GLP-1 Weight-Loss Drugs

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at